Merrimack's Slow Ramp-up For Onivyde Prompts Cutbacks
Executive Summary
CEO removed as part of 22% staff cut as Merrimack looks to increase runway while awaiting data to add first-line pancreatic cancer to the Onivyde label.
You may also be interested in...
Onivyde Too Expensive For NICE, Despite Dearth Of Pancreatic Cancer Drugs
NICE has not recommended Shire's Onivyde in draft guidance as it is not cost effective, the HTA body for England and Wales said. The pancreatic cancer treatment has also struggled to make its mark on the US market where it is being commercialized by Merrimack Pharmaceuticals.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.